Macrosalb Medi-Radiopharma

Macroaggregated Albumin labeled with technetium-99m, the active ingredient in Macrosalb Medi‑Radiopharma, is a diagnostic radiopharmaceutical presented as a kit for reconstitution (lyophilized powder) for intravenous use. It enables visualization of pulmonary blood flow and is employed in lung perfusion imaging, particularly for diagnosing pulmonary embolism and assessing regional lung function before surgery.

GNH USA supplies Macrosalb Medi‑Radiopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Macrosalb Medi‑Radiopharma is used in nuclear medicine to evaluate pulmonary perfusion and related conditions.

- Lung perfusion imaging: provides quantitative and qualitative assessment of regional pulmonary blood flow. - Pulmonary embolism diagnosis: helps detect obstructed pulmonary arteries by highlighting perfusion defects. - Pre‑operative lung function assessment: determines functional contribution of each lung segment before thoracic surgery.

Administration of Macrosalb Medi‑Radiopharma may be associated with the following adverse reactions.

Common Side Effects: - Transient chest discomfort: mild pain occurring during or shortly after injection. - Shortness of breath: brief episodes of dyspnea that resolve spontaneously. - Nausea or vomiting: mild gastrointestinal upset. - Fever or chills: low‑grade temperature rise post‑administration. - Injection site reaction: redness or swelling at the venous access point.

Serious or Rare Side Effects: - Pulmonary hypertension: sudden increase in pulmonary arterial pressure. - Severe allergic reaction: anaphylaxis with rash, swelling, or airway compromise. - Embolic events: rare large‑particle embolization causing infarction. - Acute respiratory distress: severe breathing difficulty requiring medical intervention.

Prior to using Macrosalb Medi‑Radiopharma, the following precautions should be observed. - Patient evaluation: assess for severe pulmonary hypertension or right‑heart failure before injection. - Allergy screening: inquire about known hypersensitivity to albumin or technetium‑99m compounds. - Concurrent imaging agents: avoid administering other radiopharmaceuticals within 24 hours to prevent image interference. - Pregnancy and lactation: use only if the diagnostic benefit outweighs potential fetal or infant radiation exposure. - Emergency preparedness: have resuscitation equipment and medications for anaphylaxis readily available. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake the kit.

Macroaggregated albumin labeled with technetium‑99m can interact with certain agents that affect pulmonary circulation or radiation exposure.

Major Interactions (Avoid): - High‑dose vasodilators: may exacerbate pulmonary hypotension when combined with the radiopharmaceutical. - Other radiopharmaceuticals: simultaneous use can cause overlapping gamma emissions and inaccurate imaging.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase the risk of bleeding at the injection site. - Beta‑blockers: can alter heart rate and affect perfusion imaging interpretation. - Iodinated contrast agents: may interfere with subsequent nuclear scans if administered within 24 hours.